Lisata Therapeutics Inc (LSTA)

Sector:
FINANCE
Industry:
INSURANCE
SIC:
SERVICES-MISC HEALTH & ALLIED SERVICES, NEC
CEO:
David J. Mazzo
Employees:
30
110 ALLEN ROAD, SECOND FLOOR, BASKING RIDGE, NJ 07920
908-842-0100

Caladrius Biosciences, Inc. focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia.

Data derived from most recent annual or quarterly report
Market Cap 283.832 Million Shares Outstanding60.518 Million Avg 30-day Volume 1.442 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.29
Price to Revenue0.0 Debt to Equity0.0 EBITDA-26.556 Million
Price to Book Value0.5046 Operating Margin0.0 Enterprise Value-48.673 Million
Current Ratio21.265 EPS Growth0.057 Quick Ratio20.997
1 Yr BETA 2.2652 52-week High/Low 9.38 / 0.4 Profit Margin0.0
Operating Cash Flow Growth-152.1251 Altman Z-Score-0.8175 Free Cash Flow to Firm -19.696 Million
Earnings Report2022-11-03 Earnings Report2022-11-03
View SEC Filings from LSTA instead.

View recent insider trading info

Lisata Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding LSTA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding LSTA

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2022-01-18 by MAZZO DAVID J
  • 4: filed on 2022-01-18 by GIROLAMO TODD C
  • 4: filed on 2022-01-12 by MAZZO DAVID J
  • 4: filed on 2022-01-12 by GIROLAMO TODD C
  • 4: filed on 2022-01-12 by BUCK KRISTEN K
  • 4: filed on 2022-01-12 by WHITAKER ANNE CLEM
  • 4: filed on 2022-01-12 by TRABER PETER G
  • 4: filed on 2022-01-12 by MEYERS STEVEN S
  • 4: filed on 2022-01-12 by KLOSK STEVEN M
  • 4: filed on 2022-01-12 by FLOWERS CYNTHIA LOUISE

    • Events (8k)

  • 8-K: filed on 2020-12-14:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-07-28:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-07-10:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-05-26:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-05-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-04-24:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-04-22:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-03-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-11-18:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-08-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    MAZZO DAVID J CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 631,065 2022-01-13 2

    GIROLAMO TODD C CLO, SVP OF CORP DEV

    • Officer
    		 160,827 2022-01-13 2

    MYERS STEVEN S

    • Director
    		 223,459 2022-01-10 2

    KLOSK STEVEN M

    • Director
    		 151,390 2022-01-10 1

    TRABER PETER G

    • Director
    		 149,190 2022-01-10 1

    BROWN GREGORY B

    • Director
    		 149,040 2022-01-10 1

    DAVIDSON MICHAEL H.

    • Director
    		 209,753 2022-01-10 1

    WHITAKER ANNE CLEM

    • Director
    		 182,635 2022-01-10 1

    FLOWERS CYNTHIA LOUISE

    • Director
    		 145,847 2022-01-10 1

    BUCK KRISTEN K EVP, R&D AND CMO

    • Officer
    		 351,703 2022-01-10 1

    TALAMO JOSEPH SVP AND CFO

    • Officer
    		 59,644 2020-01-13 0

    LOSORDO DOUGLAS W SEE REMARKS

    • Officer
    		 130,406 2020-01-13 0

    PRETI ROBERT A

    • SEE REMARKS
    		 No longer subject to file 2017-05-18 0

    SANFORD

    SANFORD HEALTH

    • 10% Owner
    		 1,059,322 2017-03-22 0

    WEI ERIC

    • Director
    		 176,523 2017-02-07 0

    BERMAN RICHARD J

    • Director
    		 7,177 2017-01-09 0

    NEWHALL CONSTRUCTION LTD.

    • 10% Owner
    		 1,271,186 2016-09-14 0

    PECORA ANDREW L

    • Director
    		 393,784 2016-06-22 0

    VATERS ROBERT S PRESIDENT & CFO

    • Officer
    • Director
    		 228,750 2015-08-12 0

    GREENACRE MARTYN D

    • Director
    		 88,531 2015-06-02 0

    SMITH ROBIN L EXECUTIVE CHAIR OF THE BOARD

    • Officer
    • Director
    		 347,285 2015-06-02 0

    BERNSTEIN DREW

    • Director
    		 10,000 2015-06-02 0

    VACZY CATHERINE M GENERAL COUNSEL

    • Officer
    		 71,234 2015-04-13 0

    RIMASIA CAPITAL PARTNERS MANAGER, LTD.

    RIMASIA CAPITAL PARTNERS, L.P.

    RIMASIA CAPITAL PARTNERS GP, L.P.

    RIMASIA CAPITAL PARTNERS GP, LTD.

    WEI ERIC

    • Director
    • 10% Owner
    		 2,222,988 2015-01-02 0

    DICKEY ROBERT IV CHIEF FINANCIAL OFFICER

    • Officer
    		 12,066 2014-12-31 0

    POTTER STEPHEN W EXECUTIVE VICE PRESIDENT

    • Officer
    		 14,016 2014-12-31 0

    KEIRSTEAD HANS SEE REMARKS

    • Officer
    		 0 2014-05-09 0

    DILLMAN ROBERT SEE REMARKS

    • Officer
    		 0 2014-05-09 0

    MAY LARRY ALAN CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2013-01-02 0

    RIMASIA CAPITAL PARTNERS MANAGER, LTD.

    • 10% Owner
    		 22,515,180 2012-09-17 0

    GEEHR EDWARD

    • Director
    		 0 2012-06-29 0

    SCHMIEG MARTIN E VICE PRESIDENT- CORPORATE DEV

    • Officer
    		 0 2012-06-25 0

    SACKNER-BERNSTEIN JONATHAN VP CLINICAL DEV & REG AFFAIRS

    • Officer
    		 0 2012-04-02 0

    RIMASIA CAPITAL PARTNERS, L.P.

    RIMASIA CAPITAL PARTNERS GP, L.P.

    RIMASIA CAPITAL PARTNERS GP, LTD.

    WEI ERIC

    • Director
    • 10% Owner
    		 22,529,874 2012-01-12 0

    SHI MINGSHENG SEE REMARKS

    • Officer
    • Director
    		 0 2012-01-04 0

    KOLBERT JASON SEE REMARKS

    • Officer
    		 0 2012-01-04 0

    HARRIS ALAN G SEE REMARKS

    • Officer
    		 0 2011-04-04 0

    ZHANG IAN SEE REMARKS

    • Officer
    		 0 2011-04-04 0

    ZHANG JIAN M SEE REMARKS

    • Officer
    		 0 2010-06-09 0

    SALERNO ANTHONY SEE REMARKS

    • Officer
    		 0 2010-06-09 0

    FULLBRIGHT FINANCE LTD

    • 10% Owner
    		 3,047,432 2009-12-30 0

    DUIGNAN CHRISTOPHER C VICE PRESIDENT, FINANCE

    • Officer
    		 0 2009-11-30 0

    SAMUELS LEPORE TERESA LINN VP OF SALES AND MARKETING

    • Officer
    		 0 2009-10-29 0

    SOUTHPOINT CAPITAL ADVISORS LP

    SOUTHPOINT GP, LP

    SOUTHPOINT CAPITAL ADVISORS LLC

    SOUTHPOINT GP, LLC

    BUTTS ROBERT W

    CLARK JOHN SMITH II

    • 10% Owner
    		 No longer subject to file 2009-06-18 0

    WEINREB MARK PRESIDENT

    • Officer
    		 0 2009-05-21 0

    ZUCKERMAN JOSEPH

    • Director
    		 0 2009-05-21 0

    ENHANCE BIOMEDICAL HOLDINGS LTD

    • 10% Owner
    		 4,000,000 2009-04-09 0

    MARGULA CO LLC

    • CONSULTANT
    		 0 2008-12-31 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    LISATA THERAPEUTICS INC LSTA 2022-09-26 14:15:04 UTC -4.4696 7.5396 100000
    LISATA THERAPEUTICS INC LSTA 2022-09-26 13:45:03 UTC -4.4696 7.5396 100000
    LISATA THERAPEUTICS INC LSTA 2022-09-26 13:15:04 UTC -4.4696 7.5396 100000
    LISATA THERAPEUTICS INC LSTA 2022-09-26 12:45:03 UTC -4.4696 7.5396 100000
    LISATA THERAPEUTICS INC LSTA 2022-09-23 22:15:03 UTC -4.4696 7.5396 90000
    LISATA THERAPEUTICS INC LSTA 2022-09-23 21:45:03 UTC -4.4696 7.5396 90000
    LISATA THERAPEUTICS INC LSTA 2022-09-23 21:15:03 UTC -4.4696 7.5396 90000
    LISATA THERAPEUTICS INC LSTA 2022-09-23 20:45:03 UTC -4.4696 7.5396 90000
    LISATA THERAPEUTICS INC LSTA 2022-09-23 20:15:06 UTC -4.4696 7.5396 95000
    LISATA THERAPEUTICS INC LSTA 2022-09-23 19:45:03 UTC -4.4696 7.5396 95000
    LISATA THERAPEUTICS INC LSTA 2022-09-23 19:15:03 UTC -4.4696 7.5396 95000
    LISATA THERAPEUTICS INC LSTA 2022-09-23 18:45:03 UTC -4.4696 7.5396 95000
    LISATA THERAPEUTICS INC LSTA 2022-09-23 18:15:04 UTC -4.4696 7.5396 95000
    LISATA THERAPEUTICS INC LSTA 2022-09-23 17:45:04 UTC -4.4696 7.5396 95000
    LISATA THERAPEUTICS INC LSTA 2022-09-23 17:15:04 UTC -4.4696 7.5396 95000
    LISATA THERAPEUTICS INC LSTA 2022-09-23 16:45:03 UTC -4.4696 7.5396 95000
    LISATA THERAPEUTICS INC LSTA 2022-09-23 16:15:03 UTC -4.4696 7.5396 95000
    LISATA THERAPEUTICS INC LSTA 2022-09-23 15:45:03 UTC -4.4696 7.5396 95000
    LISATA THERAPEUTICS INC LSTA 2022-09-23 15:15:03 UTC -4.4696 7.5396 95000
    LISATA THERAPEUTICS INC LSTA 2022-09-23 14:45:03 UTC -3.0362 5.3562 95000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments